Investigational therapy efzimfotase alfa shows promising Phase III results in rare bone disease
Efzimfotase alfa is an investigational enzyme replacement therapy designed to reduce injection volume
Efzimfotase alfa is an investigational enzyme replacement therapy designed to reduce injection volume
She brings 20 years of in vivo pharmacology experience across academia and industry, including senior scientific and leadership roles at Orion Pharma and Charles River
The open-label trial involved 105 adults with schizophrenia who were on a stable dose of an oral atypical antipsychotic for at least six weeks
The showcase, running March 27–31, puts a spotlight on everything from fine lines to daily sun protection
The trial demonstrated that immune responses in children were non-inferior to adults, with a similar safety profile after two standard doses of MVA-BN
The new assay consolidates screening for four major viral threats into a single workflow
Allergan also presented new insights on the growing population of patients on GLP-1 agonists for weight loss who are seeking aesthetic treatments
Sugammadex injection is bioequivalent to Merck’s Bridion injection for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery
This strategic acquisition enables CORONA Remedies to penetrate deeper into targeted specialty and offer wider accessibility
The presentations underscore the company’s deep expertise in dermatology and immunology
Subscribe To Our Newsletter & Stay Updated